Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins

References

• The NAMS Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of the North American menopause society. Menopause. 2022;29(7):767–794.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–1580.
   PubMed Web of Science ®Google Scholar
• Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47–53.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Committee opinion no. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411–415.
   PubMedGoogle Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19(4):316–328.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Bainton L, Upmalis DH, et al. Comparison of endometrial growth produced by unopposed conjugated estrogens or by micronized estradiol in postmenopausal women. Am J Obstet Gynecol. 1997;176(1):112–117.
   PubMed Web of Science ®Google Scholar
• Dittmar M. Comparison of soft tissue body composition in postmenopausal women with or without hormone replacement therapy considering the influence of reproductive history and lifestyle. Ann Hum Biol. 2001;28(2):207–221.
   PubMed Web of Science ®Google Scholar
• Hogervorst E, Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas. 2010;66(1):56–71.
   PubMed Web of Science ®Google Scholar
• Zhu L, Jiang X, Sun Y, et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461–470.
   PubMed Web of Science ®Google Scholar
• Man RY, Ting LK, Fan S, et al. Effect of postmenopausal hormone replacement therapy on lipoprotein and homocysteine levels in Chinese women. Mol Cell Biochem. 2001;225(1):129–134.
   PubMed Web of Science ®Google Scholar
• Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277–2286.
   PubMed Web of Science ®Google Scholar
• Blondon M, van HV, Wiggins KL, et al. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. J Thromb Haemost. 2014;12(6):879–886.
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Merz CN, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the women’s health initiative observational study. Menopause. 2014;21(3):260–266.
   PubMed Web of Science ®Google Scholar
• Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European prospective investigation into cancer and nutrition. Int J Cancer. 2011;128(1):144–156.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Tamimi RM, Konings P, et al. Different menopausal hormone regimens and risk of breast cancer. Ann Oncol. 2018;29(8):1771–1776.
   PubMed Web of Science ®Google Scholar
• Shufelt C, Bairey Merz CN, Pettinger MB, et al. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. Menopause. 2018;25(9):985–991.
   PubMed Web of Science ®Google Scholar
• Bulbul NH, Ozden S, Dayicioglu V. Effects of hormone replacement therapy on mammographic findings. Arch Gynecol Obstet. 2003;268(1):5–8.
   PubMedGoogle Scholar
• Gleason CE, Schmitz TW, Hess T, et al. Hormone effects on fMRI and cognitive measures of encoding: importance of hormone preparation. Neurology. 2006;67(11):2039–2041.
   PubMed Web of Science ®Google Scholar
• Silverman DH, Geist CL, Kenna HA, et al. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology. 2011;36(4):502–513.
   PubMed Web of Science ®Google Scholar
• Wroolie TE, Kenna HA, Williams KE, et al. Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17beta-estradiol versus conjugated equine estrogens. Am J Geriatr Psychiatry. 2011;19(9):792–802.
   PubMed Web of Science ®Google Scholar
• Rasgon NL, Geist CL, Kenna HA, et al. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLoS One. 2014;9(3):e89095.
   PubMed Web of Science ®Google Scholar
• Wroolie TE, Kenna HA, Williams KE, et al. Cognitive effects of hormone therapy continuation or discontinuation in a sample of women at risk for Alzheimer disease. Am J Geriatr Psychiatry. 2015;23(11):1117–1126.
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Kitchens CS, Ware MD. Coagulation and fibrinolysis in estrogen-treated surgically menopausal women. Obstet Gynecol. 1984;63(5):621–625.
   PubMed Web of Science ®Google Scholar
• Utian WH, Speroff L, Ellman H, et al. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. Menopause. 2005;12(6):708–715.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Brenner P, Mishell DR. Jr. Metabolic parameters and steroid levels in postmenopausal women receiving lower doses of natural estrogen replacement. Obstet Gynecol. 1983;62(1):94–98.
   PubMed Web of Science ®Google Scholar
• Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174(1):25–31.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Jiang X, Li X, et al. Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls. PLoS One. 2018;13(5):e0197064.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Haung YB, Kuo HF, et al. Hormone replacement therapy and risk of atrial fibrillation in taiwanese menopause women: a nationwide cohort study. Sci Rep. 2016;6:24132.
   PubMed Web of Science ®Google Scholar
• Cengiz B, Atabekoglu C, Cetinkaya E, et al. Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas. 2003;46(4):301–306.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
   PubMed Web of Science ®Google Scholar
• Blondon M, Timmons AK, Baraff AJ, et al. Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women veterans. Menopause. 2021;28(10):1125–1129.
   PubMed Web of Science ®Google Scholar
• Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989;321(5):293–297.
   PubMed Web of Science ®Google Scholar
• Abenhaim HA, Suissa S, Azoulay L, et al. Menopausal hormone therapy formulation and breast cancer risk. Obstet Gynecol. 2022;139(6):1103–1110.
   PubMed Web of Science ®Google Scholar
• Canonico M, Carcaillon L, Plu-Bureau G, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47(7):1734–1741.
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010;30(2):340–345.
   PubMed Web of Science ®Google Scholar
• Canonico M, Alhenc-Gelas M, Plu-Bureau G, et al. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause. 2010;17(6):1122–1127.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Hemker HC, Clement C, et al. Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause. 2011;18(8):873–879.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LA, Pace C, Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000;9(4):381–387.
   PubMedGoogle Scholar
• Asi N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev. 2016;5(1):121.
   PubMedGoogle Scholar
• Yang Z, Hu Y, Zhang J, et al. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017;33(2):87–92.
   PubMed Web of Science ®Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2010;172(12):1394–1403.
   PubMed Web of Science ®Google Scholar
• Fournier A, Dossus L, Mesrine S, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol. 2014;180(5):508–517.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448–454.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
   PubMed Web of Science ®Google Scholar
• Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26(8):1260–1268.
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC, et al. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol. 2009;27(31):5138–5143.
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Dossus L, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat. 2014;145(2):535–543.
   PubMed Web of Science ®Google Scholar
• Espie M, Daures JP, Chevallier T, et al. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol. 2007;23(7):391–397.
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;275(5):370–375.
   PubMed Web of Science ®Google Scholar
• Ryan N, Rosner A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clin Ther. 2001;23(7):1099–1115.
   PubMed Web of Science ®Google Scholar
• Pelissier C, Maroni M, Yaneva H, et al. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas. 2001;40(1):85–94.
   PubMed Web of Science ®Google Scholar
• Jondet M, Maroni M, Yaneva H, et al. Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas. 2002;41(2):115–121.
   PubMed Web of Science ®Google Scholar
• Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause. 2002;9(4):253–263.
   PubMed Web of Science ®Google Scholar
• Di Carlo C, Sammartino A, Di Spiezio SA, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause. 2005;12(5):520–525.
   PubMed Web of Science ®Google Scholar
• Zheng TP, Sun AJ, Xue W, et al. Efficacy and safety of cimicifuga foetida extract on menopausal syndrome in Chinese women. Chin Med J (Engl). 2013;126(11):2034–2038.
   PubMed Web of Science ®Google Scholar
• Wang YP, Ma D, Cheng XT, et al. Comparison of Cimicifuga foetida extract and different hormone therapies regarding in causing breast pain in early postmenopausal women. Gynecol Endocrinol. 2019;35(2):160–164.
   PubMed Web of Science ®Google Scholar
• Sun A, Lin S, Yu W, et al. Percutaneous estrogen in prevention of early postmenopausal bone loss in Chinese women. Chin Med J (Engl). 2002;115(12):1790–1795.
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Lorrain J, Denesle R, et al. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause. 2001;8(1):10–16.
   PubMed Web of Science ®Google Scholar
• Leeangkoonsathian E, Pantasri T, Chaovisitseree S, et al. The effect of different progestogens on sleep in postmenopausal women: a randomized trial. Gynecol Endocrinol. 2017;33(12):933–936.
   PubMed Web of Science ®Google Scholar
• Deng Y, Xue W, Wang Y, et al. Effects of different menopausal hormone replacement regimens on body composition in Chinese women. Climacteric. 2018;21(6):607–612.
   PubMed Web of Science ®Google Scholar
• Gao L, Zheng T, Xue W, et al. Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women. Climacteric. 2018;21(1):69–74.
   PubMed Web of Science ®Google Scholar
• Xue W, Deng Y, Wang YF, et al. Effect of half-dose and standard-dose conjugated equine estrogens combined with natural progesterone or dydrogesterone on components of metabolic syndrome in healthy postmenopausal women: a randomized controlled trial. Chin Med J (Engl). 2016;129(23):2773–2779.
   PubMed Web of Science ®Google Scholar
• Gao L, Zuo H, Zheng T, et al. Influence of hormone therapy or C. foetida extract on breast tenderness in postmenopausal women. Climacteric. 2018;21(3):292–297.
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273(3):199–208.
   PubMed Web of Science ®Google Scholar
• Writing Group for the Pepi Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;276(17):1389–1396.
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol. 1998;92(6):982–988.
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal estrogen/progestin interventions (PEPI) investigators. Ann Intern Med. 1999;130(4 Pt 1):262–269.
   PubMedGoogle Scholar
• Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95(1):30–37.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Karlamangla A, Huang MH, et al. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. Arch Intern Med. 2006;166(15):1578–1584.
   PubMedGoogle Scholar
• Sherwin BB, Grigorova M. Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. Fertil Steril. 2011;96(2):399–403.
   PubMed Web of Science ®Google Scholar
• Zhu SY, Deng Y, Wang YF, et al. Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trail. Gynecol Endocrinol. 2019;35(2):165–169.
   PubMed Web of Science ®Google Scholar
• Zuo H, Sun A, Gao L, et al. Effect of menopausal hormone therapy on bone mineral density in Chinese women: a 2-year, prospective, open-label, randomized-controlled trial. Med Sci Monit. 2019;25:819–826.
   PubMed Web of Science ®Google Scholar
• Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin interventions study investigators. J Clin Endocrinol Metab. 1997;82(5):1549–1556.
   PubMedGoogle Scholar
• Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas. 2005;50(2):91–97.
   PubMed Web of Science ®Google Scholar
• Matthews KA, Owens JF, Salomon K, et al. Influence of hormone therapy on the cardiovascular responses to stress of postmenopausal women. Biol Psychol. 2005;69(1):39–56.
   PubMed Web of Science ®Google Scholar
• Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488–493.
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013;8(11):e78016.
   PubMed Web of Science ®Google Scholar
• Panay N, Nappi RE, Boolell M, et al. Venous thromboembolism risk in menopausal women treated with oral estradiol/micronised progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the United States. The 20th World Congress – International Society of Gynecological Endocrinology; 2022; Florence, Italy.
   Google Scholar
• Tempfer CB, Hilal Z, Kern P, et al. Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers (Basel). 2020;12(8):2195.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Archer DF, Kagan R, et al. A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2018;132(1):161–170.
   PubMed Web of Science ®Google Scholar
• Mirkin S, Goldstein SR, Archer DF, et al. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR). Menopause. 2020;27(4):410–417.
   PubMed Web of Science ®Google Scholar
• Henderson VW. Gonadal hormones and cognitive aging: a midlife perspective. Womens Health (Lond). 2011;7(1):81–93.
   PubMedGoogle Scholar
• Rovinski D, Ramos RB, Fighera TM, et al. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res. 2018;168:83–95.
   PubMed Web of Science ®Google Scholar